EnteroBiotix completes enrolment in Phase IIa MAST trial

EnteroBiotix has announced the completion of enrolment in the Phase IIa MAST trial of EBX-102-02 in patients who are ...
STAT

Vertex says its drug successfully reduced marker of kidney disease in late-stage trial

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...

Eye on the prize: Pitt researchers study how bacteria could heal corneal wounds

Bacteria live throughout the human body. The eye was long thought to be an exception. Dr. Anthony St. Leger, a professor of ...

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...

Could a hot cup of matcha dial down the 'sneeze switch' in allergic rhinitis?

There's now another reason to love Japan's famous matcha: A study in mice suggests that the green tea powder could reduce the need to sneeze in people with nasal allergies.
Nanowerk

Chinese acupuncture meets nanotechnology for controllable, sustained pain relief

Magnetoelectric nanoparticles embedded in a hydrogel and delivered by a threaded acupuncture needle activate mast cells under ...
Pharmabiz

Aplagon doses first patient in phase 2a trial of APAC with peripheral arterial occlusive disease/chronic limb threatening ischemia

Aplagon doses first patient in phase 2a trial of APAC with peripheral arterial occlusive disease/chronic limb threatening ischemia: Helsinki, Finland Saturday, March 14, 2026, 18: ...

State Dept. Apologizes To Slovakia For Biden-Era Program: "I Think We Were Trying To Make The Maps More Gay"

Under Secretary of State for Public Diplomacy Sarah B. Rogers apologized to Slovakia and Czechia for a Biden administration ...
Targeted Oncology

Phase 2a Trial of Microbiome Therapy With Allo-HSCT Completes Enrollment

Enrollment has been completed for a phase 2a randomized clinical trial evaluating the investigational microbiome therapeutic EBX-102-02 in patients undergoing allogeneic hematopoietic stem cell ...

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT(R) (avapritinib) in Indolent Systemic Mastocytosis

Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...

Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia

Aplagon is also planning for 2026 a Phase 2 clinical trial for arteriovenous fistula (AVF) maturation failure in Europe, following the successful completion of its Phase 1 AVF trial. The study ...
News-Medical.Net on MSN

Japan's famous matcha could reduce sneezing in people with nasal allergies

There's now another reason to love Japan's famous matcha: a study in mice suggests that the green tea powder could reduce the need to sneeze in people with nasal allergies. Matcha is a bright green ...